"Let's assume we get great news for CKD and the stock goes back up to $2-$3 and RVX issues a ton of shares to fund a Phase 3 for CKD. How long would a trial like that take,... hopefully no where near as long as BETonMACE did,...?"

Similar to the pre-specified rosuvastatin vs. atorvastatin subgroup analysis for the primary MACE endpoint, there is also a pre-specified subgroup analysis of the primary MACE endpoint for those with baseline eGFR <60 vs. >60. What if apabetalone smashes MACE incidence in the baseline eGFR<60 subgroup AND the CKD sub-study shows that apabetalone significantly increases eGFR in those with baseline eGFR<60? Diabetic CKD is a high risk population. It is not outside of the realm of possibilities for Apabetalone to be approved for diabetic CKD patients for cardio AND renal indications off of BETonMACE data.

BDAZ